Document Detail

Effect of a sardine supplement on C-reactive protein in patients receiving hemodialysis.
MedLine Citation:
PMID:  17462553     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The study evaluated the effect of a canned sardine supplement in C-reactive protein (CRP) in patients on hemodialysis (HD) and the compliance and adherence to this supplement. DESIGN: This was a quasi-experimental study: Participants with a serum CRP of 5 mg/dL or less volunteered to consume a sardine supplement or were maintained on the usual cheese/ham sandwich supplement. SETTING: The study took place in two outpatient dialysis units in Lisbon, Portugal. PATIENTS: The study comprised 63 patients receiving maintenance HD three times per week for at least 6 months and an initial CRP concentration of 5 mg/dL or less. Exclusion criteria included the presence of graft vascular access or history of cancer. INTERVENTION: After a 4-week washout period, the nutritional intervention included a canned sardine sandwich for the case group (n = 31) and a cheese or ham sandwich for the control group (n = 32), to be ingested during each routine HD session, 3 times per week, for 8 weeks. MAIN OUTCOME MEASURE: Serum levels of high-sensitivity CRP were the outcome measure. RESULTS: Only 65 patients from the invited 186 patients met the inclusion criteria and agreed to eat the sardine sandwich supplement three times per week and were involved in the study. A significant proportion of 48% (n = 31, case group) consumed the sardine sandwich supplement three times per week for 8 weeks, fulfilling the requirements and completing the study. The present investigation showed that a sardine sandwich supplement had no effect on CRP levels among patients on HD. However, when participants were stratified according to tertiles of CRP distribution values at baseline, a reduction in CRP levels was found for those in the higher tertile, being higher for the case group (P = .047). Although diabetic patients were excluded from the analysis (eight in the sardine supplementation group and seven in the control group) a significant CRP reduction was found (P = .034). CONCLUSION: Although a supplement of low-dose n-3 long-chain polyunsaturated fatty acids had no effect on the plasma high-sensitivity CRP of the supplemented group, a reduction in CRP levels was found when patients were stratified for tertiles of CRP (for the upper tertile) and diabetic status (for nondiabetic patients). These findings need to be further confirmed. This canned sardine supplement was accepted by an important proportion of patients, enhancing diet variety and contributing for a greater n-3 long-chain polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid intake.
Ana Catarina Moreira; Augusta Gaspar; Maria Adelaide Serra; Jacinto Simões; José Lopes da Cruz; Teresa Freitas do Amaral
Related Documents :
11961173 - In polymyalgia rheumatica serum prolactin is positively correlated with the number of t...
21060333 - Chronic inflammation in fmf: markers, risk factors, outcomes and therapy.
9875083 - Dispersion of regional wall motion abnormality in patients with long qt syndrome.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation     Volume:  17     ISSN:  1532-8503     ISO Abbreviation:  J Ren Nutr     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-27     Completed Date:  2007-05-22     Revised Date:  2007-06-25    
Medline Journal Info:
Nlm Unique ID:  9112938     Medline TA:  J Ren Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  205-13     Citation Subset:  IM    
Dietetics-Higher School of Health Technologies, Lisbon, Portugal. <>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
C-Reactive Protein / analysis*
Fatty Acids, Omega-3 / administration & dosage
Food Preservation*
Kidney Failure, Chronic / diet therapy*,  therapy
Middle Aged
Patient Compliance
Renal Dialysis
Reg. No./Substance:
0/Fatty Acids, Omega-3; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Body composition and physical activity in end-stage renal disease.
Next Document:  Protein supplementation with sports protein bars in renal patients.